logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

< Back

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

Drugs

Cancer and Palliative Care

June 2021


Glofitamab is in clinical development for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL) and primary mediastinal large B-cell lymphoma (PMBCL). HGBCL and PMBCL are subtypes of DLBCL which is a type of blood cancer that develops when white blood cells, called lymphocytes, grow out of control. Relapsed cancer refers to cancer that initially responded to treatment but then returned. Refractory cancer refers to cancer that did not respond to treatment. The prognosis for patients with relapsed or refractory DLBCL remains poor, so there is a need to develop additional treatment options.
Glofitamab is developed as an intravenous infusion to target and eliminate certain white blood cells allowing treatment of B-cell cancers. If licensed, glofitamab would offer an alternative treatment option for adult patients with relapsed or refractory DLBCL, HGBCL and PMBCL.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts